Leiden University Scholarly Publications

Your Search

Enabled Filters

  • (-) = Burg, S.H. van der
  • (-) ≠ Groot, A.F. de
  • (-) = Berends-van der Meer, D.M.A.

Search results

  • RSS Feed
(1 - 6 of 6)
Vaccination against Oncoproteins of HPV16 for Noninvasive Vulvar/Vaginal Lesions: Lesion Clearance Is Related to the Strength of the T-Cell Response
Poelgeest, M.I.E. van; Welters, M.J.P.; Vermeij, R.; Stynenbosch, L.F.M.; Loof, N.M.; Berends-van der Meer, D.M.A.; ... ; Burg, S.H. van der 2016
Vaccination against Oncoproteins of HPV16 for Noninvasive Vulvar/Vaginal Lesions: Lesion Clearance Is Related to the Strength of the T-Cell Response
Article / Letter to editor
metadata only
Conclusions: This new study confirms that clinical efficacy of ISA101 vaccination is related to the strength of vaccine-induced HPV16-specific T-cell immunity and is an effective therapy for HPV16... Show moreConclusions: This new study confirms that clinical efficacy of ISA101 vaccination is related to the strength of vaccine-induced HPV16-specific T-cell immunity and is an effective therapy for HPV16-induced high-grade VIN/VaIN. (C) 2016 AACR. Show less
The long-term immune response after HPV16 peptide vaccination in women with low-grade pre-malignant disorders of the uterine cervix: a placebo-controlled phase II study
Steenwijk, P.J.D. van; Poelgeest, M.I.E. van; Ramwadhdoebe, T.H.; Lowik, M.J.G.; Berends-van der Meer, D.M.A.; Minne, C.E. van der; ... ; Kenter, G.G. 2014
The long-term immune response after HPV16 peptide vaccination in women with low-grade pre-malignant disorders of the uterine cervix: a placebo-controlled phase II study
Article / Letter to editor
metadata only
HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial
Poelgeest, M.I.E. van; Welters, M.J.P.; Esch, E.M.G. van; Stynenbosch, L.F.M.; Kerpershoek, G.; Meerten, E.L.V. van; ... ; Burg, S.H. van der 2013
HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial
Article / Letter to editor
metadata only
HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial
Poelgeest, M.I.E. van; Welters, M.J.P.; Esch, E.M.G. van; Stynenbosch, L.F.M.; Kerpershoek, G.; Meerten, E.L.V. van; ... ; Burg, S.H. van der 2013
HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial
Article / Letter to editor
metadata only
A placebo-controlled randomized HPV16 synthetic long-peptide vaccination study in women with high-grade cervical squamous intraepithelial lesions
Steenwijk, P.J.D. van; Ramwadhdoebe, T.H.; Lowik, M.J.G.; Minne, C.E. van der; Berends-van der Meer, D.M.A.; Fathers, L.M.; ... ; Burg, S.H. van der 2012
A placebo-controlled randomized HPV16 synthetic long-peptide vaccination study in women with high-grade cervical squamous intraepithelial lesions
Article / Letter to editor
metadata only
Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses
Welters, M.J.P.; Kenter, G.G.; Steenwijk, P.J.D. van; Lowik, M.J.G.; Berends-van der Meer, D.M.A.; Essahsah, F.; ... ; Burg, S.H. van der 2010
Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses
Article / Letter to editor
metadata only
One half of a group of 20 patients with human papillomavirus type 16 (HPV16)-induced vulvar intraepithelial neoplasia grade 3 displayed a complete regression (CR) after therapeutic vaccination with... Show moreOne half of a group of 20 patients with human papillomavirus type 16 (HPV16)-induced vulvar intraepithelial neoplasia grade 3 displayed a complete regression (CR) after therapeutic vaccination with HPV16 E6/E7 synthetic long peptides. Patients with relatively larger lesions generally did not display a CR. To investigate immune correlates of treatment failure, patients were grouped according to median lesion size at study entry, and HPV16-specific immunity was analyzed at different time points by complementary immunological assays. The group of patients with smaller lesions displayed stronger and broader vaccine-prompted HPV16-specific proliferative responses with higher IFN gamma (P = 0.0003) and IL-5 (P < 0.0001) levels than patients with large lesions. Characteristically, this response was accompanied by a distinct peak in cytokine levels after the first vaccination. In contrast, the patient group with larger lesions mounted higher frequencies of HPV16-specific CD4(+)CD25(+)Foxp3(+)T cells (P = 0.005) and displayed a lower HPV16-specific IFN gamma/IL-10 ratio after vaccination (P<0.01). No disparity in T memory immunity to control antigens was found, indicating that the differences in HPV-specific immunity did not reflect general immune failure. We observed a strong correlation between a defined set of vaccine-prompted specific immune responses and the clinical efficacy of therapeutic vaccination. Notably, a high ratio of HPV16-specific vaccine-prompted effector T cells to HPV16-specificCD4(+)CD25(+)Foxp3(+)T cells was predictive of clinical success. Foxp3(+)T cells have been associated previously with impaired immunity in malignancies. Here we demonstrate that the vaccine-prompted level of this population is associated with early treatment failure. Show less